Clinical Trials on Receptor, ErbB-2 in Peru

Total 122 results

Biocad

Completed

A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients

Human Epithelial Receptor (HER)-2 Positive Breast Cancer

Ukraine, Russian Federation, Belarus, India
Universidad Peruana Cayetano Heredia
Hospital Nacional Arzobispo Loayza

Terminated

Lactoferrin for Prevention of COVID-19 in Health Care Workers (LF-COVID)

SARS-CoV-2

Peru
Universidad Peruana Cayetano Heredia

Completed

Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19

SARS-CoV-2

Peru
Universidad Peruana Cayetano Heredia
Johns Hopkins Bloomberg School of Public Health

Completed

Feasibility Study on the Impact of Economic Incentives to Improve the Management of Type 2 Diabetes Mellitus (REDEEM-Pilot)

Diabetes Mellitus, Type 2

Peru
National Institute of Allergy and Infectious Diseases...
Comprehensive International Program of Research on AIDS

Completed

Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2)

HIV Infections | Herpesvirus 2, Human

Peru
CureVac
German Federal Ministry of Education and Research

Completed

A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Severe Acute Respiratory Syndrome | Covid19 | SARS-CoV-2 | Coronavirus

Panama, Peru
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

Breast Carcinoma | Estrogen Receptor Negative | Progesterone Receptor Negative

United States, Guam
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Astellas Pharma US, Inc.

Active, not recruiting

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Salivary Cancer

United States
National Cancer Institute (NCI)

Completed

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7

United States, Puerto Rico
Sanofi

Completed

Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin (ARTEMIS-DM)

Type 2 Diabetes Mellitus

Argentina, Colombia, Egypt, Hong Kong, India, Indonesia, Lebanon, Malaysia, Peru, Philippines, Saudi Arabia, South Africa, Thailand, Turkey
AstraZeneca

Active, not recruiting

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (FALCON)

Hormone Receptor Positive Breast Cancer

Canada, Spain, United States, Romania, Taiwan, Italy, Brazil, Peru, Russian Federation, China, Czechia, Ukraine, South Africa, Japan, Poland, Mexico, United Kingdom, Argentina, Slovakia, Turkey
AstraZeneca
Bristol-Myers Squibb

Completed

Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage

Type 2 Diabetes

Russian Federation
Sanofi

Completed

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (CHANGING)

Diabetes Mellitus, Type 2

Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Elevated CA15-3 or CEA or CA27-29

United States, Puerto Rico, Guam
SatRx LLC

Completed

Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.

Diabetes Mellitus, Type 2

Russian Federation
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Active, not recruiting

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States, Canada, Switzerland
Hoffmann-La Roche

Completed

A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Diabetes Mellitus Type 2

Australia, United States, France, Germany, Mexico, Puerto Rico, Peru
AstraZeneca

Completed

Type 2 Diabetes Mellitus Patients' Characteristics and Management by General Practitioners and Endocrinologists

Type 2 Diabetes Mellitus

Russian Federation
Al-Azhar University
Helwan University; National Liver Institute, Egypt

Completed

Advanced Endoscopy During COVID-19

COVID-19 | Cholangiocarcinoma | SARS-CoV-2 | Pancreas Cancer | Obstructive Jaundice | Cholangitis, Secondary Biliary

Singapore, Germany, United States, Egypt, Peru
Phenomix
Forest Laboratories

Terminated

Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Type 2 Diabetes

United States, Malaysia, Peru, India, Argentina, Philippines, Romania, Ukraine
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Stage IIIA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States, Canada
AstraZeneca
Bristol-Myers Squibb

Completed

An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes (SCORE)

Type 2 Diabetes

United States, Peru, Mexico, Colombia, Costa Rica
National Cancer Institute (NCI)

Completed

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
Phenomix
Forest Laboratories

Terminated

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

Type 2 Diabetes Mellitus

United States, Argentina, India, Peru, Poland, Czech Republic
Daiichi Sankyo, Inc.

Completed

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

Type 2 Diabetes

United States, Peru, Mexico
Daiichi Sankyo, Inc.

Completed

WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes

Type 2 Diabetes

United States, Peru, Mexico
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

United States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
Hoffmann-La Roche

Completed

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Diabetes Mellitus Type 2

Australia, Mexico, Taiwan, United States, Israel, Russian Federation, Slovakia, Ukraine, Guatemala, Peru, Romania
Daiichi Sankyo, Inc.

Completed

WelChol® and Insulin in Treating Patients With Type 2 Diabetes

Type 2 Diabetes

United States, Peru, Mexico
Novartis Pharmaceuticals

Completed

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications (Navigator)

Diabetes Mellitus, Type 2

Austria, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Russian Federation and more
Daiichi Sankyo, Inc.

Completed

Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes

Type 2 Diabetes

United States, Peru, Mexico
Sanofi

Completed

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (GetGoal-O)

Type 2 Diabetes

United States, Australia, Bulgaria, Canada, Denmark, Germany, Norway, Peru, Poland, South Africa, Spain, Sweden, United Kingdom
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

HER2/Neu Negative | Estrogen Receptor-positive Breast Cancer | Stage IV Breast Cancer AJCC v6 and v7

United States
Sanofi

Completed

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications (SENIOR)

Type 2 Diabetes Mellitus

United States, Australia, Spain, Korea, Republic of, Hungary, Mexico, Italy, Poland, Argentina, Canada, Colombia, France, Germany, Japan, Peru, Romania, Sweden, United Kingdom
Sanofi

Completed

Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost. (ATOS)

Diabetes

Peru, Ukraine, Colombia, Egypt, India, Indonesia, Israel, Jordan, Kuwait, Lebanon, Mexico, Philippines, Russian Federation, Saudi Arabia, Singapore, Taiwan, Thailand, United Arab Emirates
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Stage...

United States, South Africa
Phenomix
Forest Laboratories

Terminated

Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

Type 2 Diabetes Mellitus

United States, Argentina, Chile, Czech Republic, India, Peru, Poland
Phenomix
Forest Laboratories

Completed

Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Ukraine, Argentina, Malaysia, India, Romania, Thailand, Philippines, Peru
AstraZeneca

Completed

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

United States, Canada, Czechia, Germany, Russian Federation, Mexico
Sanofi

Completed

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

Type 2 Diabetes Mellitus

Brazil, Peru, United States, Australia, Canada, Chile, Germany, Guatemala, Mexico, Poland, Romania, Russian Federation, Ukraine
Bristol-Myers Squibb
Merck Sharp & Dohme LLC

Completed

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, Argentina, Canada, Mexico, Peru, Taiwan, Australia, Philippines, Thailand, Brazil, Chile, India, Russian Federation, Ukraine
Takeda

Completed

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

Type 2 Diabetes Mellitus

United States, Australia, Brazil, Bulgaria, Chile, Croatia, Estonia, Guatemala, India, Israel, Latvia, Mexico, New Zealand, Peru, Romania, Russian Federation, Serbia, South Africa, Ukraine
Sanofi
Hanmi Pharmaceutical Company Limited

Terminated

Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O)

Type 2 Diabetes Mellitus

Estonia, Spain, Ukraine, Italy, Germany, Canada, Mexico, United States, Argentina, Bulgaria, Chile, Denmark, Finland, Hungary, India, Korea, Republic of, Latvia, Lithuania, Norway, Peru, Poland, Romania, Russian Federation, Serbia, Slov... and more
AstraZeneca
Astra Zeneca, Bristol-Myers Squibb

Completed

Add-on to Thiazolidinedione (TZD) Failures

Type 2 Diabetes

Taiwan, United States, Argentina, Canada, Mexico, Puerto Rico, Philippines, India, Peru
Takeda

Completed

Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Australia, Brazil, Guatemala, India, Mexico, New Zealand, Peru, South Africa, Czech Republic, Germany, Hungary, Netherlands, Argentina
Phenomix
Forest Laboratories

Terminated

Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

Type 2 Diabetes Mellitus | Renal Impairment

United States, Russian Federation, Ukraine
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Diabetes Mellitus Type 2

Australia, Hong Kong, Colombia, Russian Federation, Germany, Hungary, Italy, Mexico, Peru, Romania, Slovakia, Brazil, El Salvador
Takeda

Terminated

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Argentina, Mexico, Chile, Peru
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (GETGOAL-P)

Diabetes Mellitus Type 2

United States, Austria, Canada, France, Germany, Greece, Guatemala, India, Mexico, Peru, Puerto Rico, Romania, Turkey
Hoffmann-La Roche

Completed

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

Diabetes Mellitus Type 2

United States, France, Switzerland, Germany, South Africa, Korea, Republic of, Puerto Rico, Canada, Taiwan, Spain, Poland, Slovakia, Thailand, Mexico, Turkey, Australia, Greece, Norway, Sweden, Peru, Romania, Argentina, United Kingdom

Clinical Trials on Receptor, ErbB-2 in Peru

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations